Norepinephrine (Levarterenol; L-Noradrenaline) is a potent and β1-selective adrenergic receptor agonist with EC50 of 5.37 μM.

NECA (5′-N-Ethylcarboxamidoadenosine) is a novel and potent adenosine receptor agonist with Ki values of 6.2, 14, and 20 nM for human A3, A1 and A2A receptors, respectively, and an EC50 of 2.4 μM for human A2B. It is centrally active in vivo and can inhibit platelet aggregation.

Istradefylline (formerly KW6002; KW 6002; KW-6002; Nourianz), a caffeine derivative, is an orally bioavailable and selective adenosine A2A receptor (A2AR) antagonist with anti-PD (Parkinson’s disease) effects..

SCH-58261 (SCH58261; SCH 58261) is a novel, potent, selective and competitive antagonist of the adenosine A2A receptor with immunomodulatory and neuroprotective effects.

ZM241385 (ZM-241385; ZM 241385) is a novel and potent adenosine A2A-receptor antagonist with immunomodulatory and antitumor effects.

Taminadenant (PBF-509; NIR-178) is a novel, oral and potent adenosine receptor antagonist used as an immunotherapy agent.

Preladenant (formerly known as MK-3814; SCH-420814) is a novel potent, selective and competitive antagonist of adenosine A2A receptor with potential immunomodulatory effects and may be used for the treatment for Parkinson’s disease.

Capadenoson (formerly also known as BAY 68-4986) is a novel, orally bioactive, potent and selective adenosine A1 receptor agonist.

Olodaterol (formerly known as BI-1744; BI1744; STRIVERDI RESPIMAT) is a ultra-long acting beta-adrenoceptor agonist approved in 2014 for use as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD) It was developed and manufactured by Boehringer-Ingelheim.

Imaradenant (AZD4635; HTL-1071) is a novel, potent, selective, orally bioavailable small molecule inhibitor of the adenosine A2A receptor (A2AR) (Ki = 1.7 nM) with potential anticancer immunomodulatory activity.